Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV20-0251 and Sintilimab in Resectable HNSCC
NCT07457281Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of GV20-0251 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Apr 2026; status: recruiting.
02
Drugs
GV20-0251
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07457281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457281.